Bulk Cetuximab Biosimilar – Research Grade – Fc-Silenced
This biosimilar is manufactured in a cGMP compliant, ISO Quality Standard 9001:2015 facility. ichorbio offers Amazon vouchers or donations to the NC3Rs for reviews of this product: click here for more information. ichorbio: the best antibodies for in vivo research.
Human IgG1 κ
This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Cetuximab. Clone C225 recognizes human EGFR.
EGFR is ubiquitously expressed and found in the plasma membrane.
EGFR is a 170 kD transmembrane glycoprotein that is part of the ErbB family of receptors within the protein kinase superfamily. EGFR is one of four closely related receptor tyrosine kinases: EGFR (ErbB-1), HER2/c-neu (ErbB-2), Her 3 (ErbB-3) and Her 4 (ErbB-4). EGFR is essential for various processes including controlling cell growth and differentiation and ductal development of the mammary glands. Ligand binding induces dimerization and autophosphorylation. It consists of a glycosylated extracellular domain which binds to EGF and an intracellular domain with tyrosine-kinase activity necessary for signal transduction. TGFα, vaccinia virus growth factor, and related growth factors can also bind to and signal through EGFR. Abnormal EGFR signaling has been implicated in inflammatory diseases such as psoriasis, eczema and atherosclerosis. Alzheimer’s disease is linked with poor signaling of the EGFR and other receptor tyrosine kinases. Furthermore, over-expression of the EGFR is linked with the growth of various tumors. EGFR has been identified as an oncogene, a gene which in certain circumstances can transform a cell into a tumor cell, which has led to the therapeutic development of anticancer EGFR inhibitors. EGFR is a well-established target for both mAbs and specific tyrosine kinase inhibitors. Anti-Human EGFR (Cetuximab) utilizes the same variable regions from the therapeutic antibody Cetuximab making it ideal for research projects
≥ 2.0 mg/ml
This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (PBS) pH 7.2 – 7.4, 150 mM NaCl with no carrier protein, potassium, calcium or preservatives added.
>99% by SDS-PAGE and HPLC
<0.5 EU/mg as determined by the LAL method
This biosimilar is stable for at least four (4) weeks when stored sterile at 2-8°C. For long term storage aseptically aliquot in working volumes without diluting and store at –80°C. Avoid Repeated Freeze Thaw Cycles.
Blocking, CyTOF®, Flow Cytometry,
Each investigator should determine their own optimal working dilution for specific applications.
Products are for research use only. Not for use in diagnostic or therapeutic procedures.